AbstractsNSCLC, metastatic1382PD - Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
NSCLC, metastatic
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2018 THE AUTHORS. Published by Elsevier Ltd. All rights reserved.